We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . More info . X close

CRISPR Market: Growth, Size, Share, and Trends

Report Code BT 6746
Published in May, 2025, By MarketsandMarkets™
Download PDF

Choose License Type

Buy Report Now Inquire Before Buying

CRISPR Market by Offering [Product (Kits, Enzymes, Libraries), Service (gRNA Synthesis, Cell Line Development, Screening, Validation)], Application (Drug Discovery, Development, Agriculture) Competitive Landscape, Company Profiles -Global Forecast to 2030

Overview

The global CRISPR market, valued at US$2.90 billion in 2024, is forecasted to grow at a robust CAGR of 11.2%, reaching US$3.21 billion in 2025 and an impressive US$5.47 billion by 2030. The growing demand for CRISPR-based gene therapies, followed by advancements in CRISPR technology, and the rising government and private investments in CRISPR technology support the market growth. The development of new vaccines for the treatment of genetic diseases and the expansion of industrial and agricultural applications are presenting strong growth opportunities for CRISPR in the coming years.

However, technical challenges associated with CRISPR technology and regulatory hurdles for CRISPR advancements are likely to hamper the market growth in the forecast period.

The key segments positively influencing the market include products, such as CRISPR kits & enzymes, which dominate due to their vital role in drug discovery and genetic research. In terms of applications, drug discovery & development applications lead the market, with pharmaceutical & biotechnology companies serving as the largest end users because of their significant investments in research and development. Additionally, the increasing adoption of CRISPR-based gene therapies further supports market growth.

CRISPR Market– Global Forecast and Key Opportunities to 2030

Attractive Opportunities in the CRISPR Market

Asia Pacific

Market growth in the Asia Pacific can be attributed to the increased pharmaceutical and biotechnology investments and the rising demand for personalized medicine.

A surge in academic collaborations and clinical research activities in areas such as personalized medicines is fueling market growth.

Expanding healthcare infrastructures and the increasing focus on precision medicine and gene therapy are expected to provide opportunities for players in the market.

The Asia Pacific CRISPR market is expected to grow at a CAGR of 12.3% during the forecast period.

Lack of skilled professionals and stringent and varied regulatory frameworks are likely to negatively impact market growth.

Global CRISPR Market Dynamics

DRIVER: Growing demand for CRISPR-based gene therapies

Gene therapies based on CRISPR technology are capable of treating unmet medical conditions by targeting the genetic basis of diseases. Patients are turning to new treatments that have the possibility of curing or dramatically improving their condition. Clinical trials in several areas of disease have had encouraging results, such as blood diseases, inherited retinal disorders, and some cancers. A milestone study in the New England Journal of Medicine in 2023 reported outcomes from decisive trials of exagamglogene autotemcel (exa-cel), a CRISPR-Cas9-based treatment for transfusion-dependent β-thalassemia (TDT) and sickle-cell disease (SCD). The trials showed that a single administration of exa-cel resulted in transfusion independence in 88% of TDT patients and abolished vaso-occlusive crises in all SCD patients under study. These findings highlight the therapeutic promise of CRISPR-based therapies for blood diseases.

In November 2023, the Medicines and Healthcare Products Regulatory Agency in the UK approved CASGEVY to treat SCD and TDT in patients over the age of 12. The US Food and Drug Administration (FDA) later approved CASGEVY to treat SCD on December 8, 2023, marking the first CRISPR-based therapy to gain regulatory approval. The increasing need for CRISPR-based gene therapies is a paradigm shift in the therapeutic approach to genetic disorders and unlocks new avenues for personalized medicine. The creation and commercialization of CRISPR-based treatments can profoundly enhance patient outcomes.

RESTRAINT: Technical challenges associated with CRISPR technology

Technical issues related to CRISPR technology are a major limitation in gene editing. Although CRISPR is extremely powerful, some barriers prevent its large-scale application. These challenges arise due to the technicalities involved in the genome editing process, off-target effects, and delivery efficiency. It is essential to overcome these technical challenges to unlock the full potential of CRISPR technology and achieve its revolutionary impact in industries. Another problem is the low efficiency of CRISPR-Cas9. The system is not always efficient at editing DNA, and this can make it less useful for some purposes. For instance, CRISPR-Cas9 has been employed to treat cancer, but it has not been highly effective in curing the disease. CRISPR-Cas9 is also a fairly costly technology. This may restrict its application in developing nations, where there is a high demand for new disease treatments like cancer and HIV/AIDS.

 

OPPORTUNITY: Development of new vaccines and treatments for genetic diseases

The development of new vaccines and therapies for genetic disorders using CRISPR technology provides a revolutionary prospect in the medical field. The accurate editing potential of CRISPR has great promise in treating infectious diseases and addressing the underlying genetic causes of most disorders. For example, Editas Medicine is carrying out a Phase I/II trial in patients with severe sickle-cell disease (SCD) but employing a CRISPR system based on a Cas12a protein instead of the better known Cas9 protein. Furthermore, Vertex Pharmaceuticals and CRISPR Therapeutics are collaborating on beta-thalassemia. The clinical trial is in Phase II.

CRISPR-mediated vaccine development allows us to respond quickly to emerging infectious disease threats, thereby equipping the healthcare sector to fight evolving threats successfully. The latest developments speak volumes about the promise of CRISPR in transforming vaccine development and the treatment of genetic diseases. The market opportunity and potential to meet unmet medical needs offer compelling reasons for research and investment in this field.

CHALLENGES: Regulatory hurdles for CRISPR advancements

Regulatory bodies across the globe are working towards formulating guidelines for CRISPR technology. This is a complex task since CRISPR is a powerful tool that can make targeted changes to DNA. The agencies need to carefully balance the possible benefits of CRISPR with potential risks (for example, off-target mutations).

The gradual evolution of regulations is generating uncertainty in the life sciences sector. Firms are not willing to go all out in funding CRISPR-based research and development without the promise that their products will be approved. This ambiguity is inhibiting the pace of innovation in the area of CRISPR. In addition, such regulatory barriers pose problems for patients who would be helped by CRISPR-based treatments since some people suffering from severe diseases are unable to get access to these treatments because they are not approved. This is an important issue considering the therapeutic potential of CRISPR-based treatments for curing or mitigating these illnesses.

Global CRISPR Market Ecosystem Analysis

The CRISPR market functions within an ecosystem that includes various stakeholders essential for designing and adopting CRISPR technologies. This ecosystem consists of raw material providers, kits & reagents manufacturers, service providers, end users, and regulatory bodies. Key market players are established companies that have been operating in the CRISPR sector for several years, boasting extensive product/service portfolios and robust global sales and marketing networks.

CRISPR Market Ecosystem

The products segment dominated the CRISPR market in 2024.

Based on offerings, the CRISPR market is segmented into products and services. The products segment is further divided into CRISPR kits & enzymes, CRISPR libraries, and other products. The services segment is further divided into gRNA synthesis & cell line development, screening & validation, and other services. Among these, the CRISPR kits & enzymes category maintained the largest market share in 2024 and is expected to expand at a strong CAGR over the forecast period. The wider availability of ready-to-use formulated kits and high-fidelity enzymes offering increased efficiency, specificity, and ease of use further heightens their acceptance. Continued product developments and increases in the number of CRISPR-based study research and clinical uses are further propelling their leading market share.

The drug discovery & development application segment accounted for the majority market share in 2024.

Based on applications, the CRISPR market is categorized into drug discovery & development , agriculture, and other applications. The drug development & discovery application segment held a major share of the CRISPR market in 2024 due to the increasing application of the technology in the identification of drug targets, validation of gene function, and the creation of disease models. The ability of the technology to edit genes with great accuracy accelerates preclinical studies and enhances the effectiveness of creating targeted therapies. The surging demand for personalized medicine and the escalating rate of clinical trials for CRISPR-edited treatments are also responsible for this dominance.

Pharmaceutical & biotechnology companies are the highest revenue-generating end-user segment in the CRISPR market.

The CRISPR products market is divided into several segments based on end users: pharmaceutical & biotechnology companies, academic & research institutes, and other end users. Pharmaceutical & biotechnology companies led the market in 2024. With increasing investments in cell and gene therapies and the necessity of accurate genetic tools for target identification and validation, these firms rely extensively on CRISPR technologies. Moreover, their financial strength allows them to implement sophisticated and tailored CRISPR products at scale, which is responsible for their huge market share.

North America Has Emerged As the Dominant Region in the CRISPR Market From 2025 to 2030.

The CRISPR market is divided by region into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America leads the global CRISPR market and is expected to maintain a significant market share during the forecast period. Within North America, the US holds a dominant position due to the presence of major research laboratories, a strong focus on innovation, and biopharmaceutical companies and CROs & CDMOs.

The US maintains a leadership role in the worldwide CRISPR industry due to its sound research ecosystem, its early embracing of gene editing technology, and its healthy funding environment. It hosts several early biotech companies that have established a position as pioneers, including CRISPR Therapeutics, Editas Medicine, and Intellia Therapeutics, and they are driving the emergence of CRISPR-based therapeutics. Furthermore, leading academic institutions and research organizations in the US, such as the Broad Institute and MIT, have been pivotal in driving CRISPR science.

HIGHEST CAGR MARKET IN 2025–2030
US IS THE FASTEST-GROWING MARKET IN THE REGION
CRISPR Market Region

Recent Developments of CRISPR Market

  • In July 2024, Agilent Technologies, Inc. (US) acquired BioVectra, Inc. (Canada), enhancing its biopharma solutions with BioVectra’s expertise in biologics and gene editing. The acquisition expanded Agilent’s capabilities in drug development and manufacturing.
  • In May 2024, Merck KGaA (Germany) acquired Mirus Bio, Inc. (US), integrating Mirus Bio's transfection technology with Merck's bioprocessing expertise. This acquisition enhanced Merck’s capabilities in viral vector manufacturing, advancing support for cell and gene therapies.
  • In March 2023, GenScript (US) announced a strategic collaboration with PersonGen-Anke Cellular Therapeutics (US) to advance cell isolation products. This partnership aimed to enhance cell therapy development and production efficiency. GenScript's CytoSinct platform was expected to support PersonGen in reducing costs and improving R&D efficiency in cell therapy.
  • In March 2023, Thermo Fisher Scientific set up a cGMP facility at the University of California, San Francisco's Mission Bay campus, to accelerate cell therapies for cancers and other hard-to-treat diseases. The facility focuses on advancing CAR-T and CRISPR technologies, offering comprehensive drug development and manufacturing services.
  • In February 2023, GenScript announced the expansion of its Singapore facility to provide a premium gene synthesis service. This marks a significant expansion of the company’s advanced gene-synthesis capability and enables GenScript to provide the service levels required for novel vaccine and therapeutics development in life sciences.

Key Market Players

Want to explore hidden markets that can drive new revenue in CRISPR Market?

Scope of the Report

Report Metric Details
Market size available for years 2023-2030
Base Year Considered 2024
Forecast period 2025-2030
Forecast units Value (USD)
Segments covered Offerings, Products, Services, Applications, and End Users
Geographies covered North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa

Key Questions Addressed by the Report

Who are the key players in the CRISPR market?
The key players in the global CRISPR market are Thermo Fisher Scientific, Inc. (US), Agilent Technologies, Inc. (US), Merck KGaA (Germany), and GenScript (US).
Which offerings segment dominates the CRISPR market?
The products segment dominated the market in 2024. Products are subsegmented into CRISPR kits & enzymes, CRISPR libraries, and other products.
Which application segment of the CRISPR market is expected to register the highest growth?
The drug discovery & development applications segment is anticipated to register the highest CAGR during the forecast period.
What is the size of the CRISPR market?
The global CRISPR market is anticipated to reach USD 5.47 billion by 2030 from USD 3.21 billion in 2025.
At what rate is the CRISPR market growing?
The global CRISPR market is expected to grow at a significant CAGR of 11.2%.

 

Personalize This Research

  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
Request A Free Customisation

Let Us Help You

  • What are the Known and Unknown Adjacencies Impacting the CRISPR Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
Customized Workshop Request

Table of Contents

Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.

TITLE
PAGE NO
INTRODUCTION
15
RESEARCH METHODOLOGY
20
EXECUTIVE SUMMARY
25
PREMIUM INSIGHTS
30
MARKET OVERVIEW
35
  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    DRIVERS
    RESTRAINTS
    OPPORTUNITIES
    CHALLENGES
  • 5.3 TECHNOLOGY ANALYSIS
    KEY TECHNOLOGIES
    - CRISPR-CAS SYSTEMS
    GRNA DESIGN & OPTIMIZATION
    - HIGH-THROUGHPUT CRISPR SCREENING
GRNA DESIGN & OPTIMIZATION
70
COMPLIMENTARY TECHNOLOGIES
- SYNTHETIC BIOLOGY
- SINGLE-CELL GENOMICS
- NEXT-GENERATION SEQUENCING
ADJACENT TECHNOLOGIES
- STEM CELL ENGINEERING
- SYNTHETIC DNA & GENE SYNTHESIS
- MICROFLUIDICS
  • 6.1 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS
  • 6.2 PRICING ANALYSIS
    AVERAGE SELLING PRICE TREND OF PRODUCT, BY KEY PLAYERS (2022-24)
    AVERAGE SELLING PRICE TREND OF PRODUCT, BY REGION (2022-24)
  • 6.3 VALUE CHAIN ANALYSIS
  • 6.4 SUPPLY CHAIN ANALYSIS
  • 6.5 ECOSYSTEM ANALYSIS
  • 6.6 PATENT ANALYSIS
  • 6.7 REGULATORY LANDSCAPE
    REGULATORY BODIES, GOVERNMENT AGENCIES, & OTHER ORGANIZATIONS
    REGULATORY FRAMEWORK
  • 6.8 KEY CONFERENCES AND EVENTS IN 2025-2026
  • 6.9 PORTER’S FIVE FORCES ANALYSIS
    THREAT OF NEW ENTRANTS
    THREAT OF SUBSTITUTES
    BARGAINING POWER OF SUPPLIERS
    BARGAINING POWER OF BUYERS
    INTENSITY OF COMPETITION RIVALRY
  • 6.10 KEY STAKEHOLDERS & BUYING CRITERIA
    KEY STAKEHOLDERS IN THE BUYING PROCESS
    BUYING CRITERIA FOR END USERS
  • 6.11 INVESTMENT AND FUNDING SCENARIO
  • 6.12 IMPACT OF AI/GEN AI ON CRISPR MARKET
  • 6.13 TRADE DATA
    IMPORT VALUE, 2020-2024
    EXPORT VALUE, 2020-2024
CRISPR MARKET, BY OFFERINGS, 2023-2030 (USD MILLION)
110
  • 7.1 INTRODUCTION
  • 7.2 PRODUCTS
  • 7.3 SERVICES
CRISPR PRODUCTS MARKET, BY TYPE, 2023-2030 (USD MILLION)
130
  • 8.1 INTRODUCTION
  • 8.2 CRISPR ENZYME & KITS
  • 8.3 CRISPR LIBRARIES
  • 8.4 OTHER PRODUCTS
CRISPR PRODUCT MARKET, BY END USER, 2023-2030 (USD MILLION)
150
  • 9.1 INTRODUCTION
  • 9.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
  • 9.3 ACADEMIC & RESEARCH INSTITUTES
  • 9.4 OTHER END USERS
CRISPR SERVICES MARKET, BY TYPE, 2023-2030 (USD MILLION)
180
  • 10.1 INTRODUCTION
  • 10.2 GRNA SYNTHESIS & CELL LINE DEVELOPMENT
  • 10.3 SCREENING & VALIDATION
  • 10.4 OTHER SERVICES
    CRISPR SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
CRISPR SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
220
  • 11.1 INTRODUCTION
  • 11.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
  • 11.3 ACADEMIC & RESEARCH INSTITUTES
  • 11.4 OTHER END USERS
CRISPR MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
240
  • 12.1 INTRODUCTION
  • 12.2 DRUG DISCOVERY & DEVELOPMENT
  • 12.3 AGRICULTURE
  • 12.4 OTHER APPLICATIONS
CRISPR MARKET, BY REGION, 2023-2030 (USD MILLION)
280
  • 13.1 INTRODUCTION
  • 13.2 NORTH AMERICA
    MACROECONOMIC OUTLOOK FOR NORTH AMERICA
    US
    CANADA
  • 13.3 EUROPE
    MACROECONOMIC OUTLOOK FOR EUROPE
    GERMANY
    UK
    FRANCE
    ITALY
    SPAIN
    REST OF EUROPE
  • 13.4 ASIA PACIFIC
    MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
    CHINA
    JAPAN
    INDIA
    REST OF ASIA PACIFIC
  • 13.5 LATIN AMERICA
    MACROECONOMIC OUTLOOK FOR LATIN AMERICA
    BRAZIL
    REST OF LATIN AMERICA
  • 13.6 MIDDLE EAST & AFRICA
    MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
COMPETITIVE LANDSCAPE
310
  • 14.1 INTRODUCTION
  • 14.2 KEY PLAYERS STRATEGIES/ RIGHT TO WIN
  • 14.3 REVENUE SHARE ANALYSIS, 2020-24
  • 14.4 MARKET SHARE ANALYSIS, 2024
  • 14.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
    STARS
    EMERGING LEADERS
    PERVASIVE PLAYERS
    PARTICIPANTS
    COMPANY FOOTPRINT: KEY PLAYERS, 2024
    - COMPANY FOOTPRINT
    - PRODUCT FOOTPRINT
    - SERVICE FOOTPRINT
    - APPLICATION FOOTPRINT
    - REGION FOOTPRINT
  • 14.6 COMPANY EVALUATION MATRIX: START-UPS/SMES, 2024
    PROGRESSIVE COMPANIES
    RESPONSIVE COMPANIES
    DYNAMIC COMPANIES
    STARTING BLOCKS
    COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
    - DETAILED LIST OF KEY STARTUPS/ SMES
    - COMPETITIVE BENCHMARKING OF KEY STARTUPS/ SMES
  • 14.7 VENDOR VALUATION AND FINANCIAL METRICS OF CRISPR MARKET
  • 14.8 BRAND/PRODUCT COMPARISON
  • 14.9 COMPETITIVE SCENARIO AND TRENDS
    PRODUCT LAUNCHES
    DEALS
    OTHER DEVELOPMENTS
COMPANY PROFILES
350
  • 15.1 KEY PLAYERS
    THERMO FISHER SCIENTIFIC INC.
    MERCK KGAA
    AGILENT TECHNOLOGIES, INC.
    GENSCRIPT
    TAKARA BIO
    CREATIVE BIOGENE
    FUJIAN SUNYBIOTECH CO.,LTD.
    EDITCO
    CARIBOU BIOSCIENCES
    LONZA
    DANAHER CORPORATION
    REVVITY
    HERA BIOLABS
    ORIGENE TECHNOLOGIES, INC.
    CELLECTA, INC.
  • 15.2 OTHER PLAYERS
    MAMMOTH BIOSCIENCES INC.
    APPLIED STEMCELL
    NEW ENGLAND BIOLABS
    TOOLGEN
    GENECOPOEIA
    TWIST BIOSCIENCES
    SYNTHEGO CORPORATION
    EGENESIS
    INSCRIPTA, INC.
    PRECISION BIOSCIENCES
APPENDIX
390
  • 16.1 INSIGHTS FROM INDUSTRY EXPERTS
  • 16.2 DISCUSSION GUIDE
  • 16.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
  • 16.4 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
  • 16.5 AVAILABLE CUSTOMIZATIONS
  • 16.6 RELATED REPORTS
  • 16.7 AUTHOR DETAILS

The research study utilized a range of secondary sources, directories, and databases to gather important information for analyzing the global CRISPR market. In addition, extensive interviews were conducted with various primary participants, including key industry members, subject-matter experts (SMEs), C-level executives from leading market players, and industry consultants. These interviews helped obtain and verify qualitative and quantitative information, allowing for a comprehensive evaluation of the market's growth scenarios. The global market size was estimated through secondary research, using both top-down and bottom-up approaches, followed by data triangulation that incorporated insights from industry experts to determine the final market size.

Secondary Research

Secondary research was primarily utilized to identify and gather information for the technical, market-oriented, and commercial analysis of the CRISPR market. The sources consulted for this study included the Broad Institute, Innovative Genomics Institute (IGI), National Institute of Food and Agriculture, International Chromosome and Genome Society (ICGS), National Human Genome Research Institute (NHGRI), Asia Pacific Society of Human Genetics (APSHG), Genetics Society of America (GSA), European Society of Human Genetics (ESHG), Centers for Common Disease Genomics (CDDG), Center for Cellular and Molecular Biology (CCMB) in India, and the Department of Biotechnology (DBT) in India.

Additional secondary sources comprised academic journals, company websites, corporate and regulatory filings such as annual reports, SEC filings, investor presentations, and financial statements; business magazines and research journals; press releases; and various trade, business, and professional associations. These sources were also instrumental in gathering essential information about key market players, market segmentation related to industry trends, developments at the regional and country levels, and technology prospects.

The secondary data collected was analyzed to determine the global CRISPR market size, which was subsequently validated through primary research.

Primary Research

Extensive primary research was conducted after gathering foundational knowledge about the global CRISPR market through secondary research. We carried out several primary interviews with market experts from both the demand and supply sides. On the demand side, we interviewed professionals from the pharmaceutical and biopharmaceutical industries, as well as from contract research organizations (CROs) and contract development and manufacturing organizations (CDMOs). On the supply side, we spoke with C-level and D-level executives, product managers, and marketing and sales managers from key manufacturers, distributors, and channel partners.

The primary interviews were conducted across six major regions: North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. Approximately 65% of the interviews involved supply-side participants, while 35% were with demand-side participants. This primary data was collected through questionnaires, emails, online surveys, personal interviews, and telephone interviews.

CRISPR Market
 Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

Both top-down and bottom-up approaches were utilized to estimate and validate the overall size of the CRISPR market. These methods were also extensively employed to assess the sizes of various subsegments within the market. The research methodology for estimating the market size includes the following steps:

CRISPR Market : Top-Down and Bottom-Up Approach

CRISPR Market Top Down and Bottom Up Approach

Data Triangulation

After arriving at the market size from the market size estimation process explained above, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Market Definition

Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) is a revolutionary tool used to edit genes in a way that resembles traditional GMO techniques. The use of the Cas9 enzymes differentiates CRISPR from other forms of genetic modification. CRISPR edits and rearranges genes by cutting out the damaged or unwanted part of the DNA, allowing the remaining DNA to be rearranged in a new way.

The report comprehensively analyzes the CRISPR market, covering a wide range of products & services such as CRISPR kits & enzymes, CRISPR libraries, gRNA synthesis, cell line development, and screening & validation.

Key Stakeholders

  • Genome editing/genome engineering product manufacturers
  • CRISPR editing/genome engineering product manufacturers
  • Suppliers and distributors of genomic instruments/systems and consumables
  • Contract manufacturing organizations
  • Pharmaceutical and biotechnology companies
  • Diagnostic centers and medical colleges
  • Contract research organizations
  • Government associations and research institutes
  • Regulatory authorities
  • Business research firms

Report Objectives

  • To define, describe, and forecast the CRISPR market by offering, product, service, application, end user (products market), end user (services market), and region
  • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
  • To analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall CRISPR market
  • To analyze the opportunities for stakeholders and provide details of the competitive landscape for market leaders
  • To forecast the size of the market segments with respect to five regions: North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
  • To profile the key players and analyze their market shares and core competencies
  • To track and analyze competitive developments, such as product/service launches, partnerships, agreements, collaborations, and expansions
  • To benchmark players within the market using the proprietary “Company Evaluation Matrix” framework, which analyzes market players on various parameters within the broad categories of business and product excellence strategy

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:

Portfolio Assessment

  • Product Matrix, which gives a detailed comparison of the product/service portfolios of the top three companies.

Company Information

  • Detailed analysis and profiling of additional market players (up to three).

Geographical Analysis

  • A further breakdown of the Rest of Asia Pacific CRISPR market into countries
  • A further breakdown of the Rest of Europe CRISPR market into countries
  • A further breakdown of the Rest of Latin America CRISPR market into countries

Previous Versions of this Report

CRISPR Market by Product (Enzymes, Kits, Libraries), Services (gRNA design, Cell Line Engineering, Screening), Application (Drug Discovery & Development, Agriculture), End User (Pharma, Biotech, CROs, Research Institutes) - Global Forecast to 2028

Report Code BT 6746
Published in Jun, 2023, By MarketsandMarkets™

CRISPR Market by Product (Enzymes, Kits, Libraries), Services (gRNA design, Cell Line Engineering, Screening), Application (Drug Discovery & Development, Agriculture), End User (Pharma, Biotech, CROs, Research Institutes) - Global Forecast to 2028

Report Code BT 6746
Published in Nov, 2018, By MarketsandMarkets™
"Our USP is "providing game-changing business opportunities reports with free customization" - so please feel free to provide us with your specific areas of interest / business challenges in much greater detail !!"

We appreciate your interest in this report. Once you fill out the form, you'll be immediately directed to an exclusive solution tailored to your needs. This high-value offering can help boost your revenue by 30% - a must-see opportunity for anyone looking to maximize growth.


By clicking the "Submit" button, you are agreeing to the Terms of Use and Privacy Policy.

Custom Market Research Services

We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements

Get 10% Free Customisation

Growth opportunities and latent adjacency in CRISPR Market

DMCA.com Protection Status